MindMed

About MindMed

MindMed is a clinical-stage biopharmaceutical company focused on developing novel products for brain health disorders, particularly in psychiatry, addiction, pain, and neurology. Our mission is to lead globally in creating treatments that enhance patient outcomes. We are advancing a pipeline of innovative drug candidates targeting serotonin, dopamine, and acetylcholine systems. MindMed is publicly traded on NASDAQ and the Canadian NEO Exchange.

Overview

• Website
• LinkedIn
• 51-200 employees
• Founded in 2019
• 7 active jobs
• Updated Apr 10, 2025